Piirkond:
Keel:

Tacholiquin® or its active ingredient tyloxapol has been successfully administered via inhalation for more than 50 years.

Tacholiquin® or its active ingredient tyloxapol has been successfully administered via inhalation for more than 50 years. Tyloxapol is a surface-active wetting agent or surfactant and has a mucolytic effect.

Its purely physical effect results from three important components:

  • Secretolysis: Viscous mucus is liquefied and can be more easily coughed up
  • Roll-up effect: Mucus is detached at its base, rolls up and can be transported away by the cilia of the respiratory tract.
  • Lower surface tension reduces the viscosity of the mucus. 

Diseases with excessive mucus production in the airways inhibit the self-cleaning function which is normally ensured by ciliary activity. Tacholiquin® helps to restore normal activity of these cilia.

Tacholiquin 1 % solution, 10x5 ml and 20 ml

Tacholiquin® or its active ingredient tyloxapol has been successfully administered via inhalation for more than 50 years. Tyloxapol is a surface-active wetting agent or surfactant and has a mucolytic effect.

Its purely physical effect results from three important components:

  • Secretolysis: Viscous mucus is liquefied and can be more easily coughed up
  • Roll-up effect: Mucus is detached at its base, rolls up and can be transported away by the cilia of the respiratory tract.
  • Lower surface tension reduces the viscosity of the mucus. 

Diseases with excessive mucus production in the airways inhibit the self-cleaning function which is normally ensured by ciliary activity. Tacholiquin® helps to restore normal activity of these cilia.

Tacholiquin® is indicated against many diseases of the respiratory tract or the lung which are particularly characterised by very viscous mucus (sputum):

  • Acute and chronic irritation of the respiratory tract
  • Inflammations
    • Sinusitis
    • Pharyngitis
    • Tracheitis
    • Bronchitis
    • Bronchiolitis
    • Pneumonia
    • Pseudo-croup (viral laryngitis in conjunction with coughing and shortness of breath)
    • Bronchial asthma
    • Bronchiectasis (abnormal widening of the bronchi)
    • Abscesses (accumulation of pus in a tissue cavity)
    • Atelectases (non-ventilated parts of the lung due to partial collapse of the lung)

Tacholiquin® can also be used whenever the respiratory tract’s self-cleaning function is impaired:

  • Impaired breathing following surgery
  • Myasthenia (nervous system disorder involving muscle weakness)
  • Tracheotomy
  • Impaired consciousness
  • Apnoea in new-borns and inability to swallow
  • Following radiation

Premature babies, infants, small children as well as adults benefit from this very well-tolerated preparation with its purely physical mode of action which does not affect the physiological conditions at the mucosa.

Tacholiquin® is suitable for inhalation and instillation. Commercially available nebulisers (such as PARIboy) can be used for inhalation. Do not use hot-water boilers. 

Näita rohkem Näita vähem

Tacholiquin

i3

Toodete elektrooniline tellimine registreeritud kasutajatele.

Külasta i3 saiti

Video

Video esitlus Oribalti kohta

Vaata videot

Kontaktid

AS Oribalt Tallinn

Kõrtsi tee 9, 75306, Rae vald
Harju maakond, Eesti 
Tel.: +372 651 5100
Fax: +372 651 5111
E-mail: est@oribalt.com

 

SIA Oribalt Riga

Dzelzavas iela 120M,
LV-1021, Rīga, Latvija
Tel.: +371 6780 2452
Fax: +371 6780 2460
E-mail: riga@oribalt.com

 

Oribalt Vilnius UAB

Laisvės pr. 75, LT-06144
Vilnius, Lietuva 
Tel.: +370 5268 8401
Fax: +370 5268 8400
E-mail: vilnius@oribalt.com

 





 

 

SIA Panpharmacy

Dzelzavas iela 120M,
LV-1021, Rīga, Latvija
Tel.: +371 6780 2452
Fax: +371 6780 2460
E-mail: riga@oribalt.com

 

Võta meiega ühendust

sõnum saadetud

Sulge